The money is not nearly enough to put two to four million people per year in South Africa on the lenacapavir jab, and even if it were, the country’s health system won’t be able to roll out the ...

At Essence Festival’s Global Black Economic Forum, Braxton joined Dr. Contessa and Raheem DeVaughn to speak candidly about HIV prevention, breast health, and taking control of your body.

NY Attorney General Letitia James wins a $202 million settlement against Gilead Sciences for illegal kickbacks.

CHICAGO Attorney General Kwame Raoul, as part of a bipartisan coalition of 49 attorneys general, announced a $202 million multistate settlement agreement ...

The scheme involved incentives to healthcare providers, leading to false claims to government programs like Medicaid.

Gilead Sciences will pay more than $200 million after admitting to a multi-year illegal kickback scheme that pushed its HIV drugs through lavish perks for prescribers. New York Attorney General ...

A landmark breakthrough in HIV prevention — a scientific feat decades in the making — received final approval from the Food ...

As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the ...

In the latest trading session, Gilead Sciences (GILD) closed at $109.06, marking a -2.7% move from the previous day. This change lagged the S&P 500's daily loss of 0.4%. Meanwhile, the Dow lost 0.98%, ...

Arcellx, Inc. advances anito-cel CAR-T therapy for relapsed/refractory multiple myeloma. Click for ACLX pivotal trials, FDA ...

Despite the recent approval of lenacapavir as a twice yearly PrEP, there is still a need for choice in HIV prevention, argue ...

Gilead Sciences Inc. closed 9.09% short of its 52-week high of $119.96, which the company achieved on March 10th.